Daily Endocrinology Research Analysis
Three impactful endocrinology papers stand out today: a mechanistic human genetics study establishing complete loss of PAX4 as a cause of transient neonatal diabetes, a large two-cohort diagnostic study refining captopril challenge test criteria for primary aldosteronism, and a meta-analysis of RCTs showing GLP-1 receptor agonists reduce fat mass but may also reduce lean mass. Together they advance disease mechanisms, diagnostic precision, and therapeutic safety in endocrine care.
Summary
Three impactful endocrinology papers stand out today: a mechanistic human genetics study establishing complete loss of PAX4 as a cause of transient neonatal diabetes, a large two-cohort diagnostic study refining captopril challenge test criteria for primary aldosteronism, and a meta-analysis of RCTs showing GLP-1 receptor agonists reduce fat mass but may also reduce lean mass. Together they advance disease mechanisms, diagnostic precision, and therapeutic safety in endocrine care.
Research Themes
- Genetic mechanisms in diabetes and beta-cell development
- Diagnostic optimization in endocrine hypertension (primary aldosteronism)
- Body composition effects of anti-obesity/antidiabetic pharmacotherapy
Selected Articles
1. Complete loss of PAX4 causes transient neonatal diabetes in humans.
This study identifies the first human cases of complete PAX4 loss-of-function causing transient neonatal diabetes, with remission in infancy and relapse in early childhood. CRISPR-edited iPSC models and CUT&RUN profiling show PAX4 directly regulates gene networks for islet development and glucose-stimulated insulin secretion, indicating species differences from mouse models.
Impact: It establishes PAX4 complete loss as a novel genetic cause of neonatal diabetes and delineates human-specific beta-cell regulatory mechanisms. This advances precision diagnosis and deepens mechanistic understanding of human islet biology.
Clinical Implications: Consider PAX4 sequencing in neonatal diabetes workups, especially in consanguineous families. Counseling should include potential remission and relapse trajectories; mechanistic insights may inform future beta-cell targeted therapies.
Key Findings
- Identified two individuals with homozygous PAX4 loss-of-function variants causing transient neonatal diabetes with relapse at 2.4 and 6.7 years.
- CRISPR-edited iPSC-derived pancreatic endoderm showed nonsense-mediated decay for p.(Arg126*), confirming functional loss.
- Integrated CUT&RUN and RNA-seq revealed PAX4 directly regulates genes involved in islet development and glucose-stimulated insulin secretion.
Methodological Strengths
- Combined human genetics with mechanistic validation using CRISPR-edited iPSCs and CUT&RUN in beta-cell models
- Clear genotype-to-function linkage (nonsense-mediated decay) and integrative multi-omics analysis
Limitations
- Small number of human cases (n=2), limiting generalizability
- Functional studies are in vitro and may not fully recapitulate in vivo human development
Future Directions: Expand case ascertainment to define penetrance and phenotypic spectrum; dissect PAX4 regulatory networks in primary human islets; explore therapeutic modulation of PAX4 targets for beta-cell resilience.
OBJECTIVE: Gene discovery studies in individuals with diabetes diagnosed within 6 months of life (neonatal diabetes, NDM) can provide unique insights into the development and function of human pancreatic beta-cells. METHODS: We performed genome sequencing in a cohort of 43 consanguineous individuals with NDM in whom all the known genetic causes had previously been excluded. We used quantitative PCR and RNA-sequencing in CRISPR-edited human induced pluripotent stem cells (iPSCs), and CUT&RUN-sequencing in EndoC-βH1 cells to investigate the effect of PAX4 loss on human pancreatic development. RESULTS: We describe the identification of homozygous PAX4 loss-of-function variants in 2 individuals with transient NDM: a p.(Arg126∗) stop-gain variant and a c.-352_104del deletion affecting the first 4 PAX4 exons. We confirmed the p.(Arg126∗) variant causes nonsense mediated decay in CRISPR-edited iPSC-derived pancreatic endoderm cells. Integrated analysis of CUT&RUN-sequencing in EndoC-βH1 cells and RNA-sequencing in PAX4-depleted islet stem cell models identified genes directly regulated by PAX4 involved in both pancreatic islet development and glucose-stimulated insulin secretion. CONCLUSION: We report the first human cases of complete loss of PAX4, establishing it as a novel cause of NDM and highlighting its role in human beta cell development. Both probands had transient NDM which remitted in early infancy but relapsed at the ages of 2.4 and 6.7 years, demonstrating that in contrast to mouse models, PAX4 is not essential for the development of human pancreatic beta-cells.
2. Comparison of different criteria of captopril challenge test for the diagnosis of primary aldosteronism.
Across large retrospective (n≈1335) and prospective (n≈296) cohorts using the saline infusion test as reference, post-captopril plasma aldosterone concentration (PAC) showed superior diagnostic accuracy for primary aldosteronism compared to post-CCT ARR or PAC suppression percentage. A practical cutoff of 11 ng/dL achieved robust sensitivity/specificity across cohorts.
Impact: Defines an empirically validated CCT cutoff and demonstrates the superiority of post-CCT PAC, which can standardize PA workflows and reduce reliance on resource-intensive confirmatory tests.
Clinical Implications: Use post-CCT PAC (≥11 ng/dL) as a primary criterion to confirm PA following ARR screening, especially where saline infusion is impractical, while considering cohort-specific trade-offs in sensitivity and specificity.
Key Findings
- Post-CCT PAC achieved AUC 0.90 (retrospective) and 0.89 (prospective), outperforming post-CCT ARR (AUC 0.73/0.71) and PAC suppression percentage (AUC 0.72/0.58).
- A PAC cutoff of 11 ng/dL yielded sensitivity/specificity of 0.89/0.66 (retrospective) and 0.77/0.84 (prospective).
- Findings were consistent across independent cohorts using the saline infusion test as the reference standard.
Methodological Strengths
- Dual-cohort design with both retrospective and prospective validation
- Use of a standardized reference (saline infusion test) and ROC-based comparison of multiple criteria
Limitations
- Specificity and sensitivity trade-offs differ between cohorts, which may limit universal application of a single cutoff
- Saline infusion test, while standard, is not the surgical outcome gold standard (e.g., adrenal venous sampling)
Future Directions: Prospective multicenter studies linking CCT cutoffs to surgical outcomes; evaluation in diverse populations and CKD/heart failure where saline infusion is contraindicated.
OBJECTIVES: The Captopril Challenge Test (CCT) is favored in the diagnosis of primary aldosteronism (PA) for its simplicity and high patient compliance, yet optimal diagnostic criteria for CCT remain controversial. This study compared the accuracy of different CCT criteria for the diagnosis of PA. METHODS: This study included retrospective and prospective cohorts. High-risk PA patients were enrolled to complete aldosterone-to-renin ratio (ARR) screening, CCT, and the saline infusion test (SIT). SIT was used as the reference standard, and receiver operating characteristic (ROC) curves were constructed to evaluate the diagnostic accuracy. RESULTS: The retrospective cohort included 871 patients with PA and 464 with EH. The AUC for PAC post-CCT in diagnosing PA was 0.90, significantly higher than that of ARR post-CCT (0.73) or PAC suppression percentage (0.72). The prospective cohort included 134 patients with PA and 162 with EH, showing an AUC for PAC post-CCT of 0.89, significantly higher than that of ARR post-CCT (0.71) or PAC suppression percentage (0.58). Using a PAC post-CCT cutoff of 11 ng/dL for diagnosing PA achieved a sensitivity of 0.89 and specificity of 0.66 in the retrospective cohort, and a sensitivity of 0.77 and specificity of 0.84 in the prospective cohort, respectively. CONCLUSION: PAC post-CCT served as a superior indicator for the diagnosis of PA, with 11 ng/dL recommended as the optimal diagnostic cutoff.
3. The effects of GLP-1 receptor agonists on body composition in patients with type 2 diabetes, overweight or obesity: A meta-analysis of randomized controlled trials.
Across 36 RCTs (n=2555), GLP-1 receptor agonists significantly reduced fat mass, body fat percentage, and both visceral and subcutaneous fat areas. Versus placebo, lean mass decreased, whereas differences versus active comparators were not significant; lean mass percentage was unchanged.
Impact: Synthesizes RCT evidence clarifying body composition trade-offs with GLP-1RAs—key for balancing weight-loss efficacy with muscle preservation in T2D/obesity care.
Clinical Implications: Monitor lean mass during GLP-1RA therapy, especially in longer-term treatment and in overweight/obese patients; pair with resistance exercise and adequate protein intake; consider body composition assessment to personalize therapy.
Key Findings
- GLP-1RAs significantly reduced fat mass, body fat percentage, visceral fat area, and subcutaneous fat area across RCTs.
- Lean mass decreased versus placebo, with more pronounced effects in overweight/obese patients and with longer treatment duration.
- No significant differences versus active comparators (oral antidiabetics, insulin, lifestyle), and lean mass percentage remained unchanged.
Methodological Strengths
- Meta-analysis of randomized controlled trials with multiple body composition endpoints
- Consistent directionality of fat reduction across measures and studies
Limitations
- Heterogeneity in measurement methods and durations; limited reporting details may affect comparability
- Lean mass effects were most evident versus placebo, potentially reflecting background therapy differences
Future Directions: Head-to-head trials with standardized DXA/BIA protocols assessing muscle strength/function; evaluate resistance training/protein supplementation adjuncts to mitigate lean mass loss.
AIM: The objective is to evaluate the impacts of glucagon-like peptide 1 receptor agonists on body composition among patients with type 2 diabetes, overweight or obesity. METHODS: We conducted an extensive search in the PubMed, Embase, and Cochrane Library databases, scanning the literature related to GLP-1RAs from the establishment of the databases to October 15, 2024, without language restrictions. Ignoring heterogeneity, a random effects model is adopted. I RESULTS: 36 randomized controlled trials were included, involving 2555 participants. The study demonstrated that GLP-1RAs conspicuously decreased fat-related outcomes, encompassing fat mass, body fat percentage, visceral fat area and subcutaneous fat area. When placebo was adopted as a control, GLP-1RAs decreased the lean mass. No significant discrepancies were detected when oral antidiabetic drugs, insulin, and lifestyle interventions were employed as controls. There was no disparity in the effect of GLP-1RAs on the lean mass percentage. CONCLUSION: This study indicates that the treatment of GLP-1RAs can decrease fat mass. Lean mass loss was observed in the majority of studies, and the effect is more prominent in overweight and obese patients as well as in those with long-term treatment. However, there was no disparity in the effect of GLP-1RAs on the lean mass percentage.